A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have ...

Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...

When the liver fails to clear toxic nitrogen waste, it can fuel liver cancer. Damaged urea cycle enzymes cause ammonia to ...

Clinicians in 5 states participated in an online survey to gauge the level of compliance with HCC surveillance guidelines. According to the survey, knowledge gaps and barriers to HCC screening in ...

Ontario becomes the first province in Canada to publicly reimburse the dual immunotherapy combination for unresectable or advanced hepatocellular carcinoma This decision marks the second OPDIVO® ...

—A recent retrospective study from Japan found no connection between previous HBV infection and incidence of HCC in patients with HCV after they have achieved SVR, counter to data found in earlier ...